Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients
- 77 Downloads
To evaluate clinical, histopathologic, and radiation (RT) dose parameters in patients with extranodal low-grade (ENLG) non-Hodgkin lymphoma (NHL) and their possible impact on local control (LC) and survival.
Materials and methods
The medical records of 159 patients with 181 histologically confirmed ENLG-NHL lesions treated at our institution were reviewed retrospectively.
The predominant histological subtype (73%) was marginal zone lymphoma (MZL). Common lesion sites were the gastrointestinal tract (GIT; 33%), skin (26%), and orbit (21%). The majority of patients (88%) presented with stage I/II disease. Thirty-three (20%) lesions were treated with reduced-dose RT (≤30.6 Gy) and 148 lesions (80%) with conventional-dose RT (>30.6 Gy), with an overall median dose of 39.6 Gy (range 4–63). The median follow-up period was 72 months. The 10-year local control (LC), Progression-free survival (PFS), and overall survival (OS) rates were 96, 65, and 82%, respectively. Higher overall response rate (ORR; 98% vs. 94%, p = 0.001) and complete response rate (CRR; 95% vs. 73%, p = 0.001) were observed in patients treated with conventional-dose regimens than in those treated with reduced-dose regimens. Ten-year PFS (p = 0.90) and OS (p = 0.40) was similar between the two dose groups. RT was well tolerated in both dose groups, with no grade 4/5 toxicities. In the multivariate analysis, RT dose and timing (upfront or salvage) were related to LC, whereas age, histology, and complete response (CR) to RT were associated with PFS. Patient age and radiation field size impacted OS.
RT is an effective and curative local treatment for early-stage FL and MZL at conventional and reduced radiation doses. Conventional-doses seems to be associated with local response improvement, without significant differences in PFS rates. Age, histology, and response to RT may influence the PFS.
KeywordsGastrointestinal tract Skin Head and neck Orbit Intensity-modulated Involved-site radiotherapy
Conflict of interest
K. Elsayad, G. Reinartz, M. Oertel, S. Rehn, J. Eismann, S. Scobioala, H. Berssenbrügge, N. Eter, C. Weishaupt, H.H. Schmidt, B. Friedrichs, I. Grünewald, W. Hartmann, G. Lenz, E. Wardelmann, N. Willich, and H.T. Eich declare that they have no competing interests.
- 14.Brierley J, Gospodarowicz MK, Wittekind C (eds) (2017) TNM classification of malignant tumours, 8th edn. John Wiley & Sons Inc, Chichester, West Sussex, UK, Hoboken, NJGoogle Scholar
- 15.Eich HT, Elsayad K (2017) Radiation therapy in peripheral T‑cell and cutaneous lymphomas. In: Wenz F (ed) Radiation oncology, vol 57. Springer, Cham, pp 1–14Google Scholar
- 20.Illidge T, Specht L, Yahalom J et al (2014) Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 89(1):49–58. https://doi.org/10.1016/j.ijrobp.2014.01.006 CrossRefPubMedGoogle Scholar
- 24.Wirth A, Gospodarowicz M, Aleman BMP et al (2013) Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study. Ann Oncol 24(5):1344–1351. https://doi.org/10.1093/annonc/mds623 CrossRefPubMedGoogle Scholar
- 27.Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210. https://doi.org/10.1016/S0140-6736(12)61763-2 CrossRefPubMedGoogle Scholar
- 31.Morschhauser F, Flinn IW, Advani R et al (2019) Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol 6(5):e254–e265. https://doi.org/10.1016/S2352-3026(19)30026-2 CrossRefPubMedPubMedCentralGoogle Scholar